Core Viewpoint - The article discusses the escalating conflict between two major companies in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the competitive dynamics and market implications of their rivalry, particularly in the context of collagen products and consumer trust [3][4][19]. Group 1: Company Conflict - The conflict between Huaxi Biological and Juzhi Biological has intensified, with accusations of potential fraud being exchanged publicly [3][4]. - Huaxi Biological's sales and stock prices have declined since 2021, while Juzhi Biological's collagen products have seen significant market success [4][19]. - The public dispute has drawn attention to the market dynamics, with another company, Jinbo Biological, benefiting from the situation by avoiding direct confrontation and achieving substantial stock price increases [4][19]. Group 2: Market Dynamics - The market for recombinant collagen products is projected to grow significantly, with a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 and 2.1938 trillion yuan by 2030 [28]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, with a gross profit margin of 92.02% [28]. - The competitive landscape is shifting, with new materials and products emerging, potentially threatening the current market positions of Huaxi and Juzhi Biological [36][37]. Group 3: Key Individuals - Yang Xia, the owner of Jinbo Biological, has seen her wealth increase significantly due to the company's stock performance, solidifying her status as a prominent figure in the industry [30][29]. - The article notes the historical context of Huaxi Biological's rise and subsequent decline, contrasting it with the current successes of Juzhi and Jinbo Biological [34][35].

Core Viewpoint - The article discusses the escalating conflict between two major companies in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the competitive dynamics and market implications of their rivalry [3][4]. Group 1: Company Conflict - The conflict between Huaxi Biological and Juzhi Biological has intensified, with accusations of potential fraud being exchanged publicly [3][4]. - Huaxi Biological's sales and stock price have declined since 2021, while Juzhi Biological's "recombinant collagen" products have seen significant growth [4][20]. - The public dispute has led to increased attention on the medical beauty sector, with Juzhi Biological's stock price rising significantly amid the controversy [20][28]. Group 2: Market Dynamics - The market for recombinant collagen products is projected to grow rapidly, with a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [28]. - Jinzhi Biological, another key player in the recombinant collagen market, reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92% [28]. - The gross profit margin for Jinzhi Biological reached 92.02% in 2024, indicating strong profitability compared to other sectors, including Moutai [28]. Group 3: Industry Competition - The article notes that the medical beauty industry is witnessing a "three-women billionaire" competition, with significant figures like Yang Xia from Jinzhi Biological and Zhao Yan from Huaxi Biological [30][34]. - The emergence of new materials in the medical beauty sector poses a potential threat to the current leaders, as consumer preferences may shift [38]. - The lack of standardized testing methods for recombinant collagen products raises concerns about quality and consumer trust, which could impact market dynamics [37].